Sugi Predict

Sugi Predict / Targets / PRLHR

PRLHR

Prolactin-releasing peptide receptor · P49683 · PRLHR on Sugi Atlas →

4,692 patent compounds predicted against PRLHR, 1,851 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL433646 SCHEMBL433646 1.00 20/20
SCHEMBL433651 SCHEMBL433651 1.00 20/20
SCHEMBL434463 SCHEMBL434463 1.00 20/20
SCHEMBL434473 SCHEMBL434473 1.00 20/20
SCHEMBL434545 SCHEMBL434545 1.00 20/20
SCHEMBL434922 SCHEMBL434922 1.00 20/20
SCHEMBL434939 SCHEMBL434939 1.00 20/20
SCHEMBL434942 SCHEMBL434942 1.00 20/20
SCHEMBL434947 SCHEMBL434947 1.00 20/20
SCHEMBL434954 SCHEMBL434954 1.00 20/20
SCHEMBL434957 SCHEMBL434957 1.00 20/20
SCHEMBL434965 SCHEMBL434965 1.00 20/20
SCHEMBL434972 SCHEMBL434972 1.00 20/20
SCHEMBL434974 SCHEMBL434974 1.00 20/20
SCHEMBL434988 SCHEMBL434988 1.00 20/20
SCHEMBL435003 SCHEMBL435003 1.00 20/20
SCHEMBL435014 SCHEMBL435014 1.00 20/20
SCHEMBL435027 SCHEMBL435027 1.00 20/20
SCHEMBL435078 SCHEMBL435078 1.00 20/20
SCHEMBL435810 SCHEMBL435810 1.00 20/20

Clinical trials — most relevant to PRLHR by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell. PHASE4UNKNOWN
The Effectiveness and Safety of the Prolonged Down-regulation Protocol for Controlled Ovarian Hyperstimulation PHASE4UNKNOWN
A Pharmacodynamic Study of Leuprorelin Gelatin-Free Formulation in Female Subjects With Uterine Fibroids. PHASE2COMPLETED
Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of Fibromyalgia PHASE2COMPLETED
Recombinant Human Prolactin for Lactation Induction PHASE2WITHDRAWN
Recombinant Human Prolactin for Lactation Induction PHASE2COMPLETED
Aripiprazole in Children With Autism: A Pilot Study PHASE2COMPLETED
The Safety and Efficacy of Recombinant Human Prolactin PHASE2COMPLETED
Recombinant Human Prolactin for Lactation Induction PHASE2COMPLETED
Ghrelin for Alcohol Use in Non-Treatment-Seeking Heavy Drinkers PHASE2COMPLETED
Growth Hormone Treatment in Children With Phelan McDermid Syndrome PHASE2COMPLETED
A Reduced Dose of Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Pregnancy Loss PHASE2NOT_YET_RECRUITING
Ziprasidone in Children With Autism: A Pilot Study PHASE2COMPLETED
Study of Prolanta™ in Recurrent or Persistent Epithelial Ovarian Cancer PHASE1UNKNOWN
Cabergoline in Metastatic Breast Cancer EARLY_PHASE1COMPLETED
Prolactin Receptor and Breast Diseases nanCOMPLETED
Dopamine D2 Receptors(D2R) Imaging in Prolactinomas nanUNKNOWN
Dopamine D2 Receptors(D2R) Imaging in Nonfunctioning Pituitary Adenoma(NFPA) nanUNKNOWN
Letrozole and Cabergoline Versus Letrozole Alone in Ovulation Induction nanCOMPLETED
Polymorphism of Extrapituitary Promoter of PRL Gene and Relationships With Serum Prolactin Levels in Acne Vulgaris. nanUNKNOWN
Blinking and Yawning in Epilepsy: The Role of Dopamine nanCOMPLETED
An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly nanAPPROVED_FOR_MARKETING
Natural History of Thyroid Function Disorders nanRECRUITING
Comparing Ovarian Stimulation for Assisted Reproduction With Two Different Forms of Pituitary Suppression nanCOMPLETED
Serum Progesterone and Threatened Abortion During Lactation nanNOT_YET_RECRUITING
Dopamine Agonists Withdrawal Study of Invasive Prolactinomas Involving the Cavernous Sinus nanUNKNOWN
KLHL14 Expression as Predicting Factor of Invasiveness in pitNET nanCOMPLETED
Direct and Cross Effects of Adaptation to Systemic Hyperthermia: Impact on Quality of Life, Neurohormonal and Psychophysiological Human Status nanCOMPLETED
The PROMISE Survey nanACTIVE_NOT_RECRUITING
Bromocriptine and Insulin Sensitivity nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PRLHR binder may also engage these)

ProteinNameSimilarity
Q64121 — 1.000 Q64121 →
Q4EW11 — 1.000 Q4EW11 →
Q6VMN6 — 1.000 Q6VMN6 →
Q91V45 — 0.975 Q91V45 →
O08726 — 0.975 O08726 →
P35365 — 0.974 P35365 →
P47800 — 0.972 P47800 →
O88854 — 0.971 O88854 →
P26255 — 0.971 P26255 →
Q924U1 — 0.971 Q924U1 →
GALR2 Galanin receptor type 2 0.970 landscape →
P56496 — 0.969 P56496 →
KISS1R KiSS-1 receptor 0.969 landscape →
P31387 — 0.969 P31387 →
P79250 — 0.969 P79250 →
NTSR1 Neurotensin receptor type 1 0.969 landscape →
Q60483 — 0.968 Q60483 →
Q9TST4 — 0.968 Q9TST4 →
Q6XXX8 — 0.968 Q6XXX8 →
Q93127 — 0.968 Q93127 →
P30729 — 0.968 P30729 →
Q5IS72 — 0.968 Q5IS72 →
P52703 — 0.968 P52703 →
P49144 — 0.968 P49144 →
HTR1B 5-hydroxytryptamine receptor 1B 0.967 landscape →
Q9JJI5 — 0.967 Q9JJI5 →
Q0EAB5 — 0.967 Q0EAB5 →
P25962 — 0.967 P25962 →
O55040 — 0.967 O55040 →
Q6XXX9 — 0.966 Q6XXX9 →